Evaluation of visual acuity, contrast sensitivity, macular thickness, and vision related quality of life post laser photocoagulation among diabetic macular edema patients
Keywords:
Diabetic macular edema, contrast sensitivity, laser photocoagulation, macular thickness, vision related quality of life, visual acuityAbstract
Objectives: This study aims to assess the treatment satisfaction post laser photocoagulation among DME patients by evaluating the visual function (visual acuity and contrast sensitivity), macular thickness, and vision-related quality of life (QoL) score post laser photocoagulation. Methods: DME patients were selected and categorized into mild, moderate, and severe groups. All patients underwent focal or grid laser photocoagulation. The visual acuity, contrast sensitivity, macular thickness, and QoL scoring were performed at baseline and at 3 months post focal or grid laser photocoagulation. QoL scores were measured using National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25). Results: A total of 61 patients (111 eyes) with DME were included in this study (mild DME, 40 eyes; moderate DME, 35 eyes; severe DME, 36 eyes). At 3 months post laser photocoagulation, moderate and severe DME showed significantly improved in the mean visual acuity (p<0.001 and p = 0.047, respectively). There was no significant difference of mean contrast sensitivity between baseline and post laser photocoagulation in each group of DME. The mean macular thickness was significantly reduced in mild DME (p<0.001) and moderate DME (p = 0.049). The mean QOL score was significantly increased in moderate DME (p = 0.002) and severe DME (p = 0.038). Conclusion: Moderate DME demonstrated a significant increase of QoL score at 3 months post laser photocoagulation treatment which is consistent with improvement of visual acuity and reduction of macular thickness. However, there was no improvement in contrast sensitivity post laser photocoagulation treatment.
References
REFERENCES
Talwar D, Sharma N, Pai A, Azad RV, Kohli A, Virdi PS. Contrast sensitivity following focal laser photocoagulation in clinically significant macular oedema due to diabetic retinopathy. Clin Exp Ophthalmol. 2001; 29(1): 17-21. doi: 10.1046/j.1442-9071.2001.00361.x.
Kisilevsky M, Hudson KMC, Flanagan JG, Nrusimhadevara RK, Guan K, Wong T, et al. Agreement of Heidelberg Retinal Tomography II macula oedema module with fundus biomicroscopy in diabetic maculopathy. Arch Ophthalmol. 2006; 124 (3): 337-342. doi: 10.1001/archopht.124.3.337.
Goebel W, Kretzchmar-Gross T. Retinal thickness in diabetic retinopathy: A study using optical coherence tomography (OCT). Retinal. 2002; 22(6): 759-767. doi: 10.1097/00006982-200212000-00012.
Knight ORJ, Chang RT, Feuer WJ, Budenz DL. Comparison of retinal nerve fiber layer measurements using time domain and spectral domain optical coherent tomography. Ophthalmology. 2009; 116(7): 1271-1277. doi: 10.1016/j.ophtha.2008.12.032.
Wenick AS, Bressler NM. Diabetic macular edema: current and emerging therapies. Middle East Afr J Ophthalmol. 2012; 19(1): 4-12. doi: 10.4103/0974-9233.92110
Farahvash MS, Aslani A, Faghihi H, Ghaffari E, Mirshahi A, Faghihi S, et al. The comparison of contrast sensitivity after 3 different treatment modalities for clinically significant macular edema. Iran J Ophthalmol. 2010; 22(4): 66-72.
Puell MC, Benitez-Del-Castillo JM, Martinez-De-La-Casa J, Sanchez-Ramos C, Vico E, Perez-Carrasco MJ, et al. Contrast sensitivity and disability glare in patients with dry eyes. Acta Ophthalmol Scand. 2006; 84(4): 527-531. doi: 10.1111/j.1600-0420.2006.00671.x.
Hariprasad SM, Mieler WF, Grassi M, Green JL, Jager RD, Miller L. Vision related quality of life in patient with diabetic macular oedema. Br J Ophthalmol. 2008; 92(1): 89-92. doi: 10.1136/bjo.2007.122416.
Tranos PG, Topouzis F, Stangos NT, Dimitrakos S, Economidis P, Harris M, et al. Effect of laser photocoagulation treatment for diabetic macular oedema on patient’s vision-related quality of life. Curr Eye Res. 2004; 29(1): 41-49. doi: 10.1080/02713680490513191.
Bandello F, Polito A, Del Barello M, Zamella N, Isola M. “Light†versus “classic†laser treatment for clinically significant diabetic macular oedema. Br J Ophthalmol. 2005; 89(7): 864-870. doi: 10.1136/bjo.2004.051060.
Ang A, Tong L, Vernon SA. Improvement of reproducibility of macular volume measurement using the Heidelberg retinal tomography. Br J Ophthalmol. 2000; 84(10): 1194-1197. doi: 10.1136/bjo.84.10.1194.
Wilkinson CP, Ferris 3rd FL, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular oedema disease severity scales. Ophthalmology. 2003; 110(9): 1677-1682. doi: 10.1016/S0161-6420(03)00475-5.
Romero-Aroca P. Managing diabetic macular edema: the leading cause of diabetes blindness. World J Diabetes. 2011; 2(6): 98-104. doi: 10.4239/wjd.v2.i6.98.
Bhagat N, Grigorian RA, Tutela A, Zarbin M A. Diabetic macula edema: Pathogenesis and treatment. Surv Ophthalmol. 2009; 54(1): 1-32. doi: 10.1016/j.survophthal.2008.10.001.
Pamu NJ, Rao VJ, Chandana-Priyanka S. Effect of laser photocoagulation on contrast sensitivity, visual acuity and colour vision in patients of diabetic macular edema. Int J Adv Res. 2019; 7(2): 801-805. doi:10.21474/IJAR01/8548.
Al-Akily SA, Bamashmus MA, Gunaid AA. Causes of Visual impairment and blindness among Yemenis with diabetes: a hospital-based study. East Mediterr Health J. 2011; 17(11): 832-837. doi: 10.26719/2011.17.11.831.
Hudson C, Flanagan JG, Turner GS, Chen HC, Young LB, McLeod D. Correlation of a scanning laser derived oedema index and visual function following grid laser treatment for diabetic macular oedema. Br J Ophthalmol. 2003; 87(4): 455-461. doi: 10.1136/bjo.87.4.455.
Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE Study. ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118(4): 615-625. doi: 10.1016/j.ophtha.2011.01.031.
Greenstein VC, Chen H, Hood DC, Holopigian K, Seiple W, Carr RE. Retinal function in diabetic macular edema after focal laser photocoagulation. Invest Ophthalmol Vis Sci. 2000; 41(11): 3655-3664.
Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as a primary treatment of diabetic macular edema. Retina. 2007; 27(9): 1187-1195. doi: 10.1097/IAE.0b013e31815ec261.
Chan WC, Tsai SH, Wu AC, Chen LJ, Lai CC. Current treatments of diabetic macular edema. Int J Gerontol. 2011; 5(4): 183-188. doi.org/10.1016/j.ijge.2011.09.013.
Degenring RF, Aschmoneit I, Kamppeter B, Budde WW, Jonas JB. Optical coherence tomography and confocal scanning laser tomography for assessment of macular edema. Am J Ophthalmol. 2004; 138(3): 354-361. doi: 10.1016/j.ajo.2004.04.021.
Yang CS, Cheng CY, Lee FL, Hsu WM, Liu JH. Quantitative assessment of retinal thickness in diabetic patients with and without clinically significant macular edema using optical coherence tomography. Acta Ophthalmol Scand. 2001; 79(3): 266-270. doi: 10.1034/j.1600-0420.2001.790311.x.
Katz G, Levkovitch-Verbin H, Treister G, Belkin M, Ilany J, Polat U. Mesopic foveal contrast sensitivity is impaired in diabetic patients without retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010; 248(12): 1699-1703. doi: 10.1007/s00417-010-1413-y.
Davidov E, Breitscheidel L, Clouth J, Reips M, Happich M. Diabetic retinopathy and health- related quality of life. Graefes Arch Clin Exp Ophthalmol. 2009; 247(2): 267-272. doi: 10.1007/s00417-008-0960-y.
Diabetic Retinopathy Clinical Research Network Writing Committee, Haller JA, Qin H, Apte RS, Beck RR, Bressler NM, et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2008; 117(6): 1087-1093. doi: 10.1016/j.ophtha.2009.10.040.
Ockrim ZK, Sivaprasad S, Falk S, Roghani S, Bunce C, Gregor Z, et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. Br J Ophthalmol. 2008; 92(6): 795-799. doi: 10.1136/bjo.2007.131771.
Downloads
Published
Issue
Section
License
JBCS Publication Ethics
JBCS is committed to ensure the publication process follows specific academic ethics. Hence, Authors, Reviewers and Editors are required to conform to standards of ethical guidelines.
Authors
Authors should discuss objectively the significance of research work, technical detail and relevant references to enable others to replicate the experiments. JBCS do not accept fraudulent or inaccurate statements that may constitute towards unethical conduct.
Authors should ensure the originality of their works. In cases where the work and/or words of others have been used, appropriate acknowledgements should be made. JBCS do not accept plagiarism in all forms that constitute towards unethical publishing of an article.
This includes simultaneous submission of the same manuscript to more than one journal. Corresponding author is responsible for the full consensus of all co-authors in approving the final version of the paper and its submission for publication.
Reviewers
Reviewers of JBCS treat manuscripts received for review as confidential documents. Therefore, Reviewers must ensure the confidentiality and should not use privileged information and/or ideas obtained through peer review for personal advantage.
Reviews should be conducted based on academic merit and observations should be formulated clearly with supporting arguments. In cases where selected Reviewer feels unqualified to review a manuscript, Reviewer should notify the editor and excuse himself from the review process in TWO (2) weeks time from the review offer is made.
In any reasonable circumstances, Reviewers should not consider to evaluate manuscripts if they have conflicts of interest (i.e: competitive, collaborative and/or other connections with any of the authors, companies, or institutions affiliated to the papers).
Editors
Editors should evaluate manuscripts exclusively based on their academic merit. JBCS strictly do not allow editors to use unpublished information of authors without the written consent of the author. Editors are required to take appropriate responsive actions if ethical complaints have been presented concerning a submitted manuscript or published paper.
CONFLICT OF INTEREST
Journal of Biomedical and Clinical Sciences requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a ‘competing interests section at the end of the manuscript listing all competing interests (financial and non-financial). Where authors have no competing interests, the statement should read ,The authors have declared that no competing interests exist. Editors may ask for further information relating to competing interests.
Editors and reviewers are also required to declare any competing interests and will be excluded from the peer review process if a competing interest exists. Competing interests may be financial or non-financial. A competing interest exists when the authors interpretation of data or presentation of information may be influenced by their personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the article.
HUMAN AND ANIMAL RIGHTS
All research must have been carried out within an appropriate ethical framework. If there is suspicion that work has not taken place within an appropriate ethical framework, Editors will follow the Misconduct policy and may reject the manuscript, and/or contact the author(s) institution or ethics committee. On rare occasions, if the Editor has serious concerns about the ethics of a study, the manuscript may be rejected on ethical grounds, even if approval from an ethics committee has been obtained.
Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. Further information and documentation to support this should be made available to Editors on request.
Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declaration outlines fundamental principles to adhere to when conducting research in animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.
A statement detailing compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, Editors may contact the ethics committee for further information.
INFORMED CONSENT
For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the manuscript, this includes to all manuscripts that include details, images, or videos relating to individual participants.
DATA SHARING POLICY
JBCS strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files, in machine-readable format (such as spreadsheets rather than PDFs) whenever possible
Authors who do not wish to share their data must state that data will not be shared, and give the reason.
COPYRIGHT NOTICE
The JBCS retains the copyright of published manuscripts under the terms of the Copyright Transfer Agreement. However, the journal permits unrestricted use, distribution, and reproduction in any medium, provided permission to reuse, distribute and reproduce is obtained from the Journal's Editor and the original work is properly cited.
While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
Copyright (c) 2023 Journal of Biomedical and Clinical Sciences (JBCS)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
